Chlamydia pneumoniae and Cardiovascular Disease.

Area of Science:

• Infectious disease
• Cardiovascular pathology
• Microbiology

Background:

• Chlamydia pneumoniae (C. pneumoniae) is a respiratory pathogen implicated as a potential risk factor for cardiovascular disease.
• Epidemiologic data linking C. pneumoniae to cardiovascular disease remain controversial.
• Histopathologic and microbiologic studies consistently detect C. pneumoniae DNA and antigens in atherosclerotic arteries, suggesting an association.

Purpose of the Study:

• To review the evidence for an etiologic role of C. pneumoniae in atherosclerosis.
• To evaluate the potential of C. pneumoniae as a target for cardiovascular disease prevention and treatment.

Main Methods:

• Review of histopathologic, microbiologic, in vitro, and animal studies.
• Analysis of preliminary clinical trial data on antimicrobial therapy for coronary artery disease.

Main Results:

• C. pneumoniae has been cultured from atherosclerotic arteries.
• In vitro studies demonstrate C. pneumoniae can induce foam cell formation, LDL oxidation, and inflammatory responses.
• Animal models have been developed to study atherosclerosis initiation and enhancement.
• Preliminary trials of antimicrobial agents for secondary prevention show modest results.

Conclusions:

• The etiologic role of C. pneumoniae in atherosclerosis initiation, acceleration, or acute ischemia is still debated.
• Further research is needed, including improved diagnostic tools, diverse animal models, and primary prevention clinical trials.
• Results from ongoing large clinical trials on secondary prevention are anticipated but may not be definitive.